Headlines > All Regulatory & Safety News
Akzo Nobel profits up on divestment windfall
04-Feb-2005 - Akzo Nobel has reported a sharp rise in profits for 2004, but warned that 2005 would be tough and that further divestments in its chemicals portfolio are planned.
MAbs to replace ineffective conventional therapies
03-Feb-2005 - The European monoclonal antibody therapeutics market is set to grow at a compound annual growth rate (CAGR) of 34.1 per cent to $11.4 billion (€8.7 billion) by 2011. The growth is fuelled by the need for safe and effective treatment alternatives to autoimmune and inflammatory disorders.
Singapore makes pharma manufacturing output target
02-Feb-2005 - Singapore's manufacturing output recorded 33 per cent growth in 2004, achieving this target one year ahead of schedule and exceeding projected figures compiled in 2000, writes Wai Lang Chu.
Pharma industry applauds animal extremism bill
02-Feb-2005 - Pharmaceutical industry groups today welcomed new government legislation, which ensures animal extremists who are found guilty of 'economic damage' to research laboratories will face imprisonment of five years.
Pharma industry applauds animal extremism bill
01-Feb-2005 - Pharmaceutical industry groups today welcomed new government legislation, which ensures animal extremists who are found guilty of "economic damage" to research laboratories will face imprisonment of five years.
Genencor/Danisco tie the knot
31-Jan-2005 - The long-standing relationship between biotechnology company Genencor and Danish ingredients firm Danisco is to be cemented via the merger of the two companies.
UK backs bioprocessing with £3m grant
31-Jan-2005 - The UK government has given the national biotechnology industry trade group £3 million (€4.3m) in funding to support the development of bioprocessing, continuing a string of projects aimed at boosting the UK biotech sector.
Merck trims down again with electronic unit sale
31-Jan-2005 - Merck KGaA is planning to sell its electronic chemicals business to BASF for €270 million, freeing it up to focus on its pharmaceutical, chemical and liquid crystal businesses.
UK National Biomanufacturing Centre on track for '06 start-up
26-Jan-2005 - Construction of the UK National Biomanufacturing Centre, an ambitious project aimed at helping biotechnology start-ups get their product ideas into clinical trials, is progressing on schedule and should be ready to start production at the beginning of next year.
Transgenic specialist Pharming raises €7m
26-Jan-2005 - Pharming of the Netherlands, which is pioneering the use of transgenic animals for the production of biologics, has raised €7 million in new funding and will use the proceeds to advance its portfolio of clinical drug candidates.
NIR, Raman set to drive process spectroscopy market
25-Jan-2005 - The global market for spectroscopic equipment used in process monitoring is tipped to grow by 30 per cent between now and 2009, helped by an increasing focus on process analytical technologies (PAT) to streamline the drug manufacturing process.
REACH debated ahead of Parliamentary reading
24-Jan-2005 - The European Parliament embarked on a new round of deliberations over the controversial REACH legislation last week, amid intense lobbying by groups representing the chemicals industry, animal rights activists and environmentalists.
Activists having impact on pharma suppliers in UK
24-Jan-2005 - Increasing numbers of suppliers are being forced to stop providing their services to companies and organisations engaged in animal research, according to the Association of the British Pharmaceutical Industry.
Animal extremists' intimidation scares suppliers
24-Jan-2005 - Figures released by the Association of the British Pharmaceutical Industry (ABPI) has revealed that the level of intimidation posed by animal extremists reaches as far as the suppliers who do business with companies involved with animal research.
Mixed fortunes in first quarter for Chr Hansen
24-Jan-2005 - Growth in Asian and South American markets boost sales for Danish firm Chr Hansen, counterbalancing a fall in revenue in North America for the first quarter of the year.
Sigma-Aldrich to buy cell culture group JRH
19-Jan-2005 - Australia's CSL, the world's largest manufacturer of blood plasma products, has agreed to sell its JRH Biosciences division to Sigma-Aldrich for $370 million (€283m) in cash. JRH makes cell culture and sera products used in the production of biopharmaceuticals.
People on the move
19-Jan-2005 - New Year, new job. Busy times for personnel in the pharmaceutical technology sector, with a series of new appointments. In-PharmaTechnologist.com provides a round-up.
Wacker-Chemie buys ProThera
18-Jan-2005 - Wacker-Chemie is to acquire German biotechnology company ProThera, based in Jena, to boost its presence in the biologics manufacturing sector. ProThera will now operate as Wacker Biotech.
Plant molecular farming set to boom?
18-Jan-2005 - Despite burgeoning demand for biopharmaceutical drugs, little progress is being made toward the improving efficiency and reducing costs in conventional biomanufacturing processes using microbial or mammalian fermentation systems.
Aceto reveals 'biogeneric' ambitions
17-Jan-2005 - US chemicals company Aceto has broken cover and is now racing to develop a leading player in the market for generic versions of biologic drugs, even though the regulatory route to approval of these products is far from established.
Groupe Novasep merger completes
17-Jan-2005 - The marriage between US chemicals group Dynamic Synthesis and French separations specialist Novasep has been completed, creating what the new company claims is a unique company to serve the life sciences industry.
Rosy outlook for generic API sector?
13-Jan-2005 - The market for low-cost generic drugs looks set to be buoyant for the foreseeable future, both in Europe as a whole and in France, according to Hubert Olivier, president of the French subsidiary of the leading German generics group Ratiopharm.
Peptide market finally ripening?
13-Jan-2005 - Peptide drugs look like they may finally fulfil their promise, after years of what has largely been disappointment, if figures released in a new market research report prove accurate.
Choice of asthma inhaler 'makes no difference'
11-Jan-2005 - New treatment guidelines have concluded that there are no significant differences between the aerosol therapy devices used for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), as long as they are used as instructed.
Drug firms to publish all trial data
07-Jan-2005 - In response to accusations of a cover up over negative data and placing patient safety at risk, pharmaceutical companies worldwide have agreed to reveal the results of clinical trial drug data.
Regulatory & Safety: Most Popular...
Spotlight
  ICH sends Q11 guidelines to EU, US & Japanese regulatorsThe ICH has sent its Q11 guidelines on APIs to regulatory bodies in the US, European Union... |
  in-Pharmatechnologist.com's review of Interphex 2012in-Pharmatechnologist.com was at Interphex 2012 in New York, US to launch the revamped version of our website and speak... |
 Effective controls still lacking for continuous processing says Interphex panelContinuous processing is still hamstrung by a lack of control systems and is not ready for specific... |
 BASF buys omega-3 maker Equateq citing pharma potentialBASF has bought omega-3 fatty acid maker Equateq, citing its pharmaceutical and dietary supplements businesses as key... |
 EMA outlines manufacturing quality docs for biologics trialsThe EMA has published final guidelines on manufacturing quality documents needed for biologics entering clinical trials. |